Skip to content

Search

Search

Close this search box.

News & Media

Home > News & Media

Search

September 20, 2023

The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

2023

2022

2021

2020

2019

2023

September 20, 2023

The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

September 14, 2023

Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC

September 13, 2023

Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

August 29, 2023

Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

August 22, 2023

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

August 22, 2023

Highlights of Asieris Pharmaceuticals 2023 Semi-Annual Report

August 15, 2023

Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

August 11, 2023

Asieris Announces Positive Result from Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer

Asieris has completed the China Phase III Bridging Trial Enrollment of Hexvix®, a Diagnostic Drug for Bladder Cancer

Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

Highlights of Asieris Pharmaceuticals 2022 Annual Report

Asieris’ subsidiary makes significant progress in its commercialization strategy by obtaining the “Drug Distribution License”

February 20, 2023

NMPA accepted the registration applications for Uro-G and Uro-3500

February 9, 2023

Asieris Drug Plays Pivotal Role to Help UCSF Save a Life

February 7, 2023

Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies

January 17, 2023

Asieris Appoints Dr. Linda Wu as Chief Development Officer

2022

December 12, 2022

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

December 12, 2022

Asieris’ Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study

December 3, 2022

The First IBCC Unveiled in Hainan

November 14, 2022

Asieris named “2022 TOP 20 Most Influential Innovative Enterprises in Small Molecule Drugs”

November 11, 2022

The Oral APL-1202 in Combination with PD-1 inhibitor Tislelizumab as Neoadjuvant Therapy has Entered Phase II Clinical Study

November 10, 2022

Asieris Obtained IND Approval from US FDA for APL-1401, a New Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

November 4, 2022

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

October 29, 2022

Asieris Pharmaceuticals 2022 Q3 Quarterly Report

September 15, 2022

Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance

August 30, 2022

Asieris Included in the SSE STAR Biology and Medicine Index

August 25, 2022

Highlights of Asieris 2022 Semi-Annual Report

August 25, 2022

Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy

August 22, 2022

Asieris on Science and Technology Innovation Board “2022 Most Innovative Companies” List

August 11, 2022

Now Hiring: Business Development Director (Remote)

August 11, 2022

Now Hiring: Biomarker Scientist (Onsite, Mountain View)

August 11, 2022

Now Hiring: Protein Scientist (Onsite, Mountain View)

August 11, 2022

Now Hiring: Bioinformatics Scientist (Onsite, Mountain View)

August 11, 2022

Now Hiring: Research Associate or Sr. RA (Onsite, Mountain View)

August 10, 2022

Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board

Asieris’ Multinational Phase III Clinical Trial for the Non-Surgical Treatment of HSIL Has Completed Enrollment

The First Domestic Case in Boao, Ushering in a New Option for Diagnosing Bladder Cancer

Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open

2022 ASCO, Asieris Presented a Study Protocol of Muscle Invasive Bladder Cancer(MIBC)

Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting

Asieris Pharmaceuticals 2022 Q1 Quarterly Report

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

Now Hiring: Lab Manager (San Francisco)

Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

Hexvix® Has Obtained CDE Approval to Carry Out Clinical Real-World Evidence Study

February 24, 2022

Now Hiring: Clinical Pharmacologist

February 24, 2022

Now Hiring: Research Associate / Senior Research Associate

February 16, 2022

Asieris to Increase Presence at ASCO GU 2022

February 11, 2022

Hexvix® Has Obtained the Approval from the NMPA for Phase Ⅲ Clinical Trial

February 1, 2022

Now Hiring: Lab & Office Manager (San Francisco)

January 27, 2022

Now Hiring: Scientist / Senior Scientist (San Francisco)

January 7, 2022

Asieris Pharmaceuticals Lands on STAR Market

January 4, 2022

World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients

2021

December 27, 2021

Bladder cancer diagnosis drug Hexvix® completed first patient procedure in Bo’ao Lecheng

November 2, 2021

Now Hiring: Biology Director (San Francisco)

October 13, 2021

The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients

September 26, 2021

Asieris Named One of Top 30 Chinese Innovative Enterprises in Small Molecule Drugs

September 22, 2021

Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research

Asieris Announces First Patient Treated in Europe in APRICITY, the Multinational Phase III Clinical Trial of APL-1702, Cevira®

The U.S. FDA Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients

Asieris and Sinopharm Enter into Strategic Partnership to Accelerate Commercialization of Asieris Products

Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab

Asieris Appoints Dr. Tie-Lin Wang as Senior Vice President, Head of Discovery Chemistry and Pre-Clinical Development

Asieris and Lecheng Sinopharm Entered into a Strategic Cooperation Agreement

January 26, 2021

Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

January 25, 2021

Asieris Appointed Dr. Yong Xue as Chief Medical Officer and Mr. Xinming Jiang as VP of Sales and Marketing

2020

December 12, 2020

Company Name Change Announcement

November 28, 2020

Asieris Awarded China Top 100 Innovative Pharmaceutical Enterprises

November 12, 2020

Asieris Announces First Patient Enrollment in the Global Phase III Clinical Trial for APL-1702

November 11, 2020

Asieris Announces the Completion of their Series D Round of Financing

October 30, 2020

Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)

October 29, 2020

Asieris’ APL-1501 Approved for Phase I Clinical Trial in Australia

Asieris Received China NMPA’s Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)

Asieris Appointed Dr. Susan Wang as Senior Vice President of Global Business Development

Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization

Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

2019

December 19, 2019

Asieris Wins Fierce Innovation Awards – Life Sciences Edition 2019

September 18, 2019

Asieris Pharmaceuticals to Participate at CBIIC

August 16, 2019

Asieris Debuted Cevira® at 2019 COGA

Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira®

Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial

Asieris’s Executives to Participate in the Upcoming Asia Pharma R&D Leaders Summit 2019

Asieris CEO to Host CEO Roundtable at Upcoming WuXi Healthcare Forum 2019

January 1, 2019

Asieris to Participate in the Upcoming 12th European Life Sciences CEO Forum

About Us
Pipeline
Technology

News & Media
Partnership
Investors

Join Us
Contact Us
Term of Use
Privacy

Linkedin-in Twitter Envelope

@2014-2023 Asieris Pharmaceuticals. All Rights Reserved.

English
- English
- 中文

English
- English
- 中文

English
- English
- 中文

About Us
Pipeline
Technology
- TIMN
- PADD
- FASTac
News
- News
- Awards
- Media
- PR Contact
Partnership
- Collaboration
- Contact us
Investors
Join Us
- Openings
Contact

About Us
Pipeline
Technology
- TIMN
- PADD
- FASTac
News
- News
- Awards
- Media
- PR Contact
Partnership
- Collaboration
- Contact us
Investors
Join Us
- Openings
Contact

Search